SEARCH

SEARCH BY CITATION

References

  • 1
    Jitschin R, Mougiakakos D, Von Bahr L, et al. Alterations in the cellular immune compartment of patients treated with third-party mesenchymal stromal cells following allogeneic hematopoietic stem-cell transplantation. Stem Cells 2013;31:17151725.
  • 2
    Battiwalla M, Hematti P. Mesenchymal stem cells in hematopoietic stem cell transplantation. Cytotherapy 2009;11:503515.
  • 3
    Le Blanc K, Frassoni F, Ball L, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: A phase II study. Lancet 2008;371:15791586.
  • 4
    Le Blanc K, Rasmusson I, Sundberg B, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004;363:14391441.
  • 5
    Prasad VK, Lucas KG, Kleiner GI, et al. Efficacy and safety of ex-vivo cultured adult human mesenchymal stem cells (prochymal(TM)) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study. Biol Blood Marrow Transplant 2011;17:534541.
  • 6
    Ringden O, Uzunel M, Sundberg B, et al. Tissue repair using allogeneic mesenchymal stem cells for hemorrhagic cystitis, pneumomediastinum and perforated colon. Leukemia 2007;21:22712276.
  • 7
    Paczesny S. Discovery and validation of graft-versus-host disease biomarkers. Blood 2013;121:585594.
  • 8
    Sabatino M, Ren J, David-Ocampo V, et al. The establishment of a bank of stored clinical bone marrow stromal cell products. J Transl Med 2013;10:23.
  • 9
    Harris AC, Ferrara JL, Braun TM, et al. Plasma biomarkers of lower gastrointestinal and liver acute GVHD. Blood 2011;119:29602963.
  • 10
    Levine JE, Logan BR, Wu J, et al. Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: A blood and marrow transplant clinical trials network study. Blood 2012;119:38543860.
  • 11
    Westin JR, Saliba RM, De Lima M, et al. Steroid-refractory acute GVHD: Predictors and outcomes. Adv Hematol 2011;2011:601953.
  • 12
    von Bahr L, Sundberg B, Lonnies L, et al. Long-term complications, immunologic effects, and role of passage for outcome in mesenchymal stromal cell therapy. Biol Blood Marrow Transplant 2012;18:557564.
  • 13
    Sundin M, Barrett AJ, Ringden O, et al. HSCT recipients have specific tolerance to MSC but not to the MSC donor. J Immunother 2009;32:755764.
  • 14
    Lucchini G, Dander E, Pavan F, et al. Mesenchymal stromal cells do not increase the risk of viral reactivation nor the severity of viral events in recipients of allogeneic stem cell transplantation. Stem Cells Int 2012;2012:690236.
  • 15
    Srinivasan R, Chakrabarti S, Walsh T, et al. Improved survival in steroid-refractory acute graft versus host disease after non-myeloablative allogeneic transplantation using a daclizumab-based strategy with comprehensive infection prophylaxis. Br J Haematol 2004;124:777786.
  • 16
    Macmillan ML, Blazar BR, DeFor TE, et al. Transplantation of ex-vivo culture-expanded parental haploidentical mesenchymal stem cells to promote engraftment in pediatric recipients of unrelated donor umbilical cord blood: Results of a phase I-II clinical trial. Bone Marrow Transplant 2009;43:447454.
  • 17
    Ren J, Jin P, Sabatino M, et al. Global transcriptome analysis of human bone marrow stromal cells (BMSC) reveals proliferative, mobile and interactive cells that produce abundant extracellular matrix proteins, some of which may affect BMSC potency. Cytotherapy 2011;13:661674.